Holen Sie sich die Stockscreener-App
9.97
0.00%
0.00
Handel nachbörslich:
9.96
-0.010
-0.10%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa
Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia
BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI - Yahoo
Sector Update: Health Care Stocks Lean Lower Premarket Friday - marketscreener.com
BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com
Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewswire
Orladeyo approved for reimbursement in the Netherlands - Angioedema News
Marburg Virus Disease Pipeline 2025: Therapies Under - openPR.com
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 46.47% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability By Investing.com - Investing.com Nigeria
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Australia
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
California State Teachers Retirement System Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Wellington Management Group LLP - Defense World
Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Approved for Reimbursement in Netherlands - marketscreener.com
BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCR - GuruFocus
Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement - Investing.com Australia
BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries - marketscreener.com
BioCryst (BCRX) Gains Approval in Netherlands for ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major Eu - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | BCRX Stock News - GuruFocus
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - GlobeNewswire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
New Strong Buy Stocks for June 4th - MSN
Orladeyo effective in HAE patients of different ages, data show - Angioedema News
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth By Investing.com - Investing.com South Africa
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 04 - marketscreener.com
BioCryst at Jefferies Conference: Promising Pipeline and Financial Growth - Investing.com
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Best Momentum Stock To Buy For June 4th - Barchart.com
biocryst pharmaceuticals extends cfo consulting agreement By Investing.com - Investing.com South Africa
Best Momentum Stock to Buy for June 4th - TradingView
biocryst pharmaceuticals extends cfo consulting agreement - Investing.com
BioCryst Extends Consulting Agreement with Former CFO - TipRanks
BioCryst Pharmaceuticals Inc (BCRX) Shares Up 3.59% on Jun 3 - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 7 Strategic Hires, Grants 47,250 Restricted Stock Units - Stock Titan
2.13%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):